Back to search

Article

Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer

2023-05-23

Abstract excerpt

Immune checkpoint inhibitors (ICI) are important treatment options for metastatic non-small cell lung cancer (NSCLC). However, not all patients benefit from ICIs and can experience immune related adverse events (irAEs). Limited understanding exists for germline determinants of ICI efficacy and toxicity, but human leukocyte antigen (HLA) has emerged as a potential predictive biomarker. We obtained HLA genotypes fro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
b9c592e5-0625-537c-aece-3255c6ecdfb3
DOI
10.21203/rs.3.rs-2929223/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancerDOI 10.21203/rs.3.rs-2929223/v1
Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade.Semantic proximity
HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.Semantic proximity
HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors.Semantic proximity
PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non–Small Cell Lung CancerSemantic proximity
Frequency changes in HLA-I alleles: A marker to guide immunotherapy in lung adenocarcinoma patients and its relationship with tumor mutational burden and PD-L1 expression.Semantic proximity
Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingSemantic proximity
Association of HLA class I homozygosity with unfavorable clinical outcomes in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitor as first-line therapySemantic proximity
HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started.Semantic proximity
Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.Semantic proximity
Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancerSemantic proximity
Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy.Semantic proximity
HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.Semantic proximity
Select a neighboring publication to make it the new centre.